Rajesh ChopraNew Brunswick, NJ

8495620, Jul 23, 2013

Mar 6, 2008

12/043440

Rajesh Chopra - Union NJ, US
SweeFen Goh - Hartsdale NY, US
Richard Thomas Goodwin - Dobbs Ferry NY, US
Stephen K. Kibby - Carlsbad CA, US
Rakesh Mohan - Cortlandt Manor NY, US
Igor Naumov - Plano TX, US
Thomas Dean Rosinski - Frisco TX, US
George A. Schroeder - Port Murray NJ, US

International Business Machines Corporation - Armonk NY

G06F 9/445
G06F 9/44

717174, 717168, 717171, 717172

A system and method allow a user to extract the set of customizations performed on an application and use these to estimate the time and effort and cost of (a) migrating to a new version of the application and/or (b) consolidating systems. The user can browse the extracted data and select configuration elements for re-use. After downloading the one or more configurations and comparing them, the user selects elements of the configurations for re-use. The first step is to scan one or more application systems and extract the configuration data using a surveyor. The method according to the invention automatically identifies configuration differences. The user then selects configuration elements for re-use. A graphic user interface (GUI) can be provided which allows the user to make these selections by dragging and dropping selected elements to a “To Be” configuration. The selected configurations are then uploaded and installed on an instance of the application.

2011025, Oct 20, 2011

Feb 3, 2011

13/020031

Rajesh Chopra - Summit NJ, US
Yuhong Ning - San Diego CA, US
Sabita Sankar - Portland OR, US
Shuichan Xu - San Diego CA, US
Weiming Xu - San Diego CA, US

A61K 31/5383
C12Q 1/68
A61K 31/437
A61K 31/4985
A61K 31/4709
A61J 1/00
A61K 31/519
A61K 31/5377
A61K 31/498
A61K 31/4738
A61P 35/00
A61K 31/53
A61K 31/52

5142302, 514243, 435 618, 514303, 514249, 5142632, 5142631, 51426323, 5142342, 5142325, 514293, 206570

Provided herein are methods for treating and/or preventing a cancer or a tumor syndrome in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having cancer or a tumor syndrome, characterized by a LKB1 and/or AMPK gene or protein loss or mutation.

2014004, Feb 13, 2014

Aug 8, 2013

13/962786

Rajesh Chopra - Summit NJ, US
Anita Gandhi - Bernardsville NJ, US

Celgene Corporation - Summit NJ

C07D 413/14

5142352

Provided herein are methods of using compounds and compositions for modulating leukocytic activity, including activity of B cells and/or T cells monocytes, macrophages, and other lymphoid or myeloid-derived cell types, in immune-related diseases or inflammatory diseases. Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.

2018020, Jul 26, 2018

Nov 15, 2017

15/814330

- Summit NJ, US
Rajesh CHOPRA - Summit NJ, US
Laura CORRAL - La Jolla CA, US
Maria Yinglin WANG - San Diego CA, US
Pilgrim JACKSON - San Diego CA, US

G01N 33/50
G01N 33/574

Use of cereblon-associated proteins as biomarkers for clinical sensitivity to cancer, inflammatory diseases, and patient response to drug treatment.

2017036, Dec 21, 2017

Jan 24, 2017

15/414329

- SUMMIT NJ, US
Anita GANDHI - Bernardsville NJ, US
Michelle F. WALDMAN - Florham Park NJ, US
Rajesh CHOPRA - Summit NJ, US
Michael AMATANGELO - Newtown PA, US
Chad BJORKLUND - Summit NJ, US

C12Q 1/68
A61K 31/5377
G01N 33/68
G01N 33/574
A61K 31/454
A61K 31/517
C07K 14/47

Provided herein are cereblon isoforms and methods of their use as biomarkers for treating a disease, disorder, or condition with a treatment compound, e.g., thalidomide, lenalidomide, pomalidomide, 3-(5-amino-2-methyl-4-oxoquinazolin-3 (4H)-yl)-piperidine-2,6-dione, or (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione.

2017024, Aug 24, 2017

Dec 5, 2014

15/518472

- Summit NJ, US
Anita GANDHI - Bernardsville NJ, US
Rajesh CHOPRA - Summit NJ, US
Anke KLIPPEL - Westfield NJ, US

G01N 33/574
A61K 31/45
A61K 31/506
C12Q 1/68
A61K 31/5377

A method of identifying a subject having a solid tumor who is likely to be responsive to a treatment compound, comprising: administering the treatment compound to a subject having the solid tumor; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject, and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker.

2017012, May 11, 2017

Jul 10, 2015

15/323173

- Summit NJ, US
Anita Gandhi - Bernardsville NJ, US
Kenichi Takeshita - New York NY, US
Rajesh Chopra - Summit NJ, US

A61K 31/517
C07K 16/28
A61K 39/395

Provided herein are methods of treating, preventing and/or managing lymphomas and leukemias by administering to a patient Compound A (3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, in combination with an anti-CD20 antibody or ibrutinib, or a pharmaceutically acceptable salt or solvate thereof

2015027, Oct 1, 2015

Oct 23, 2013

14/438120

- Summit NJ, US
Rajesh Chopra - Summit NJ, US
Olivier Hermine - Palaiseau, FR
Ivan Cruz Moura - Montrouge, FR
Michael Dussiot - Chatillon, FR
Thiago Trovati Maciel - Paris, FR
Aurelie Fricot - Paris, FR

CELGENE CORPORATION - Summit NJ

G01N 33/74
C07K 14/705
C12Q 1/68

Provided herein are methods of treating diseases associated with anemia or ineffective erythropoiesis by using the level and/or activity of a ligand of an activin receptor, in particular, Growth differentiation factor 11 (GDF11), as an indicator of responsiveness of a patient to the treatment, efficacy of the treatment, or appropriate dosage for the treatment with an activin type II receptor inhibitor.